Precision Biosciences (DTIL) Total Current Liabilities (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Total Current Liabilities of $7.8 million for Q1 2026, down 37.42% year-over-year from $12.4 million in Q1 2025, and down 12.99% quarter-over-quarter from $8.9 million in Q4 2025.
Precision Biosciences (DTIL) Total Current Liabilities (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Total Current Liabilities for 9 consecutive years, with $7.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 37.42% year-over-year to $7.8 million; the TTM figure through Mar 2026 stood at $7.8 million (down 37.42% YoY), while the FY2025 annual figure was $8.9 million, down 40.5% from the prior year.
- Total Current Liabilities retreated to $7.8 million in Q1 2026 per DTIL's latest filing, from $8.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $61.1 million in Q3 2022 and bottomed at $7.8 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $32.9 million across 5 years, with a median of $33.0 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 67.64% — and 2024, when it slumped 76.33%.
- Precision Biosciences' Total Current Liabilities stood at $59.7 million in 2022, then decreased by 16.22% to $50.0 million in 2023, then plunged by 70.03% to $15.0 million in 2024, then plunged by 40.5% to $8.9 million in 2025, then retreated by 12.99% to $7.8 million in 2026.
- Business Quant data shows DTIL's Total Current Liabilities at $7.8 million in Q1 2026, $8.9 million in Q4 2025, and $15.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 630.93 Mn |
| 10 | Precision Biosciences | 227.96 Mn | 140.42 Mn | - | 7.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.14 Mn |
| Mar 31, 2026 | 7.76 Mn |
| Dec 31, 2025 | 8.91 Mn |
| Sep 30, 2025 | 15.00 Mn |
| Jun 30, 2025 | 13.57 Mn |
| Mar 31, 2025 | 12.39 Mn |
| Dec 31, 2024 | 14.98 Mn |
| Sep 30, 2024 | 11.98 Mn |
| Jun 30, 2024 | 32.96 Mn |
| Mar 31, 2024 | 33.34 Mn |
| Dec 31, 2023 | 49.99 Mn |
| Sep 30, 2023 | 50.62 Mn |
| Jun 30, 2023 | 56.40 Mn |
| Mar 31, 2023 | 46.86 Mn |
| Dec 31, 2022 | 59.66 Mn |
| Sep 30, 2022 | 61.15 Mn |
| Jun 30, 2022 | 53.92 Mn |
| Mar 31, 2022 | 29.11 Mn |
| Dec 31, 2021 | 35.98 Mn |
| Sep 30, 2021 | 36.48 Mn |